Mohamad Reza Ashoori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mohamad Reza Ashoori has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Nosratollah Zarghami
Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran
5 shared publications - Majid Mobasseri
Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Mohammad Rahmati
Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran
2 shared publications - Abolfazl Akbarzadeh
Razi Drug Research Center Iran University of Medical Sciences Tehran Iran
1 shared publication Abolghasem Mohammadi
Department of Plant Breeding & Biotechnology, Faculty of Agriculture, University of Tabriz, Iran
1 shared publicationAli Asgharzadeh
Tehran Institute of Psychiatry, Iran University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 28 December 2018
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 44 (5) , 667-675
Apelin-13 serum levels in type 2 diabetic obese women: possible relations with microRNAs-107 and 375
Objective: Apelin, an adipocytokine, is up-regulated by insulin and suppresses pancreatic insulin secretion. One of the key microRNAs in insulin resistance caused by obesity, is microRNA-107. MicroRNA-375 is expressed in the pancreatic islet cells. We aimed to explore apelin-13 and microRNA-107 and 375 in obese women with type 2 diabetes (T2D). Materials and Methods: Fifty obese women with newly diagnosed T2D and 50 non-diabetic obese women, as controls, were selected. Quantitative PCR and ELISA were used to measure the expression of microRNA-107 and 375 and Apelin-13 concentration, respectively. The role of apelin-13 was investigated in an in vitro model. Apoptosis was evaluated by flow cytometry. Results: Apelin-13 levels in diabetics were significantly more than controls (p=0.012). The expressions of microRNA-107 and 375 of diabetic group were increased, in comparison to the control group. There was no correlation between apelin-13 and microRNA-107 and 375 in diabetic and control groups. Significant correlations between apelin-13 and serotonin (p<0.001) and estimated average glucose (p<0.02) and insulin (p<0.03) were only observed in the diabetic group. Conclusion: Serum levels of apelin-13 and circulating microRNA-107 and 375 could be used as biomarkers for diabetes, particularly in obese subjects. However, more study is needed in this field.
- 28 December 2018
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 44 (5) , 667-675
Apelin-13 serum levels in type 2 diabetic obese women: possible relations with microRNAs-107 and 375
Objective: Apelin, an adipocytokine, is up-regulated by insulin and suppresses pancreatic insulin secretion. One of the key microRNAs in insulin resistance caused by obesity, is microRNA-107. MicroRNA-375 is expressed in the pancreatic islet cells. We aimed to explore apelin-13 and microRNA-107 and 375 in obese women with type 2 diabetes (T2D). Materials and Methods: Fifty obese women with newly diagnosed T2D and 50 non-diabetic obese women, as controls, were selected. Quantitative PCR and ELISA were used to measure the expression of microRNA-107 and 375 and Apelin-13 concentration, respectively. The role of apelin-13 was investigated in an in vitro model. Apoptosis was evaluated by flow cytometry. Results: Apelin-13 levels in diabetics were significantly more than controls (p=0.012). The expressions of microRNA-107 and 375 of diabetic group were increased, in comparison to the control group. There was no correlation between apelin-13 and microRNA-107 and 375 in diabetic and control groups. Significant correlations between apelin-13 and serotonin (p<0.001) and estimated average glucose (p<0.02) and insulin (p<0.03) were only observed in the diabetic group. Conclusion: Serum levels of apelin-13 and circulating microRNA-107 and 375 could be used as biomarkers for diabetes, particularly in obese subjects. However, more study is needed in this field.
- 1 December 2017
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 11, S919-S923
An overview on biological functions and emerging therapeutic roles of apelin in diabetes mellitus
- 1 December 2017
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 11, S919-S923
An overview on biological functions and emerging therapeutic roles of apelin in diabetes mellitus
- Open Access
- 27 September 2017
- Published by Taylor & Francis in Journal of Endocrinology, Metabolism and Diabetes of South Africa
- Vol. 22 (3) , 47-50
Investigating the effects of Lactobacillus casei on some biochemical parameters in diabetic mice
Aims: Diabetes mellitus is a metabolic disorder characterised by inadequate pancreatic insulin secretion or the insulin present being unable to perform its function properly. Consistent with the beneficial effects of probiotics and their ability to lower glucose levels, an impact on diabetes treatment is also expected. The aim of this study was to evaluate the effect of Lactobacillus casei on various either biochemical parameters in a diabetic mice model. Methods: In the present study, 24 mice were divided into diabetic and control groups. Further, each group was categorised into two subgroups. The diabetic and control subgroups were fed carrot juice or Lactobacillus casei in carrot juice. Diabetes was induced by streptozotocin (STZ). For 30 days, the mice were fed 2 ml carrot juice, and Lactobacillus casei in carrot juice (with lactobacillus 109 cfu/ml) by gavage. Then, blood samples were collected to assay biochemical parameters. Results: The results of this study showed that Lactobacillus casei (ATCC39392) significantly reduced blood glucose (BG) levels in diabetic mice receiving the probiotic, but did not cause a significant change in BG levels in control mice receiving the probiotic. When comparing insulin, insulin-like growth factor I (IGF-I) and C-peptide in the four groups, it was found that insulin and C-peptide were significantly different in all groups except for the control group treated with a mixture of probiotic Lactobacillus casei and carrot juice. Conclusion: Our results showed that probiotic Lactobacillus casei effectively reduces BG levels in diabetic mice treated with this bacterium.
- 27 September 2017
- Published by Taylor & Francis in Journal of Endocrinology, Metabolism and Diabetes of South Africa
- Vol. 22 (3) , 47-50
Open AccessInvestigating the effects of Lactobacillus casei on some biochemical parameters in diabetic mice
Aims: Diabetes mellitus is a metabolic disorder characterised by inadequate pancreatic insulin secretion or the insulin present being unable to perform its function properly. Consistent with the beneficial effects of probiotics and their ability to lower glucose levels, an impact on diabetes treatment is also expected. The aim of this study was to evaluate the effect of Lactobacillus casei on various either biochemical parameters in a diabetic mice model. Methods: In the present study, 24 mice were divided into diabetic and control groups. Further, each group was categorised into two subgroups. The diabetic and control subgroups were fed carrot juice or Lactobacillus casei in carrot juice. Diabetes was induced by streptozotocin (STZ). For 30 days, the mice were fed 2 ml carrot juice, and Lactobacillus casei in carrot juice (with lactobacillus 109 cfu/ml) by gavage. Then, blood samples were collected to assay biochemical parameters. Results: The results of this study showed that Lactobacillus casei (ATCC39392) significantly reduced blood glucose (BG) levels in diabetic mice receiving the probiotic, but did not cause a significant change in BG levels in control mice receiving the probiotic. When comparing insulin, insulin-like growth factor I (IGF-I) and C-peptide in the four groups, it was found that insulin and C-peptide were significantly different in all groups except for the control group treated with a mixture of probiotic Lactobacillus casei and carrot juice. Conclusion: Our results showed that probiotic Lactobacillus casei effectively reduces BG levels in diabetic mice treated with this bacterium.
- 1 September 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 93, 1326-1336
MicroRNAs and adipocytokines: Promising biomarkers for pharmacological targets in diabetes mellitus and its complications
- 1 September 2017
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 93, 1326-1336
MicroRNAs and adipocytokines: Promising biomarkers for pharmacological targets in diabetes mellitus and its complications
- Open Access
- 18 August 2016
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 45 (6) , 1222-1226
pH sensitive insulin-loaded nanohydrogel increases the effect of oral insulin in diabetic rats
Background: There are different methods for insulin administration in diabetic patient. Nano-hydrogel is one of the most talented drug carrier for its sensitivity to environmental stimulus. Methods and results: NIPAAm–MAA–HEM copolymers were synthesized by radical chain reaction. The copolymers were characterized with Scanning electron microscopy (SEM) and Transient electron microscopy (TEM). Copolymers were loaded with regular insulin by modified double emulsion method. Diabetic rats are used for feeding insulin-loaded nanohydrogel. Analysis of the results from the measurement of the amount of blood insulin from the rats blood that received insulin in nanohydrogel loaded form compared with rats that received pure insulin is significantly high, which confirm that insulin has been able to pass from the stomach acid barrier by nanohydrogel and is absorbed from the intestine. Blood sugar levels from tested rats indicate that with increasing amount of insulin, blood sugar levels fall down. Conclusion: Our study confirms that insulin has been able to pass from the stomach acid barrier by nanohydrogel and be absorbed from the intestine.
- 18 August 2016
- Published by Taylor & Francis in Artificial Cells, Nanomedicine, and Biotechnology
- Vol. 45 (6) , 1222-1226
Open AccesspH sensitive insulin-loaded nanohydrogel increases the effect of oral insulin in diabetic rats
Background: There are different methods for insulin administration in diabetic patient. Nano-hydrogel is one of the most talented drug carrier for its sensitivity to environmental stimulus. Methods and results: NIPAAm–MAA–HEM copolymers were synthesized by radical chain reaction. The copolymers were characterized with Scanning electron microscopy (SEM) and Transient electron microscopy (TEM). Copolymers were loaded with regular insulin by modified double emulsion method. Diabetic rats are used for feeding insulin-loaded nanohydrogel. Analysis of the results from the measurement of the amount of blood insulin from the rats blood that received insulin in nanohydrogel loaded form compared with rats that received pure insulin is significantly high, which confirm that insulin has been able to pass from the stomach acid barrier by nanohydrogel and is absorbed from the intestine. Blood sugar levels from tested rats indicate that with increasing amount of insulin, blood sugar levels fall down. Conclusion: Our study confirms that insulin has been able to pass from the stomach acid barrier by nanohydrogel and be absorbed from the intestine.